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R E V I E W  A R T I C L E
 .Introduction
Acute respiratory distress syndrome (ARDS) is a life threatening 
respiratory condition characterized by hypoxemia, and stiff 
lungs (1-4); without mechanical ventilation most patients 
would die. ARDS represents a stereotypic response to many 
different inciting insults and evolves through a number of 
different phases: alveolar capillary damage to lung resolution 
to a fibro-proliferative phase (3). The pulmonary epithelial and 
endothelial cellular damage is characterized by inflammation, 
apoptosis, necrosis and increased alveolar-capillary permeability, 
which lead to development of alveolar edema (3). Since its 
first description in 1967 (4), there have been a large number of 
studies addressing various clinical aspects of the syndrome (risk 
factors, epidemiology, treatment) as well as studies addressing 
its pathogenesis (underlying mechanisms, biomarkers, genetic 
predisposition). A search of PubMed using the search terms: 
“Acute Respiratory Distress Syndrome” yields >20,000 journal 
articles. However, despite this intense research activity, there 
are very few effective therapies for ARDS other than the use of 
lung protection strategies. This lack of therapeutic modalities is 
certainly related to the complex, pathogenesis of this syndrome 
with multiple signaling pathways activated depending on the 
type of lung injury. In addition, the lack of sensitive and specific 
diagnostic criteria to diagnose ARDS has hampered progress. 
To partially address the latter concern a recent consensus group 
made a number of changes to the previous American-European 
Consensus Conference definition of ARDS (5,6).
In the present review article, we will summarize the key 
features of the new definition of ARDS, which has been recently 
proposed from a panel of experts. In addition, we will also 
provide a brief overview of innovative therapeutic options that 
are being assessed in the management of ARDS, including gene 
therapy, and the administration of mesenchymal stem cells.
 .Updated definition of ARDS
ARDS is a syndrome with multiple risk factors that trigger 
the acute onset of respiratory insufficiency. The pathogenic 
mechanisms vary depending on the inciting insult, but as 
demonstrated on autopsy findings, there are a number of 
common pathological pulmonary features (7), such as increased 
permeability as reflected by alveolar edema due to epithelial 
and endothelial cell damage, and neutrophil infiltration in 
the early phase of ARDS. Until recently, the most accepted 
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definition of ARDS for use at the bedside or to conduct clinical 
trials (1,8) was the American-European Consensus Conference 
(AECC) definition, published in 1994 (9). ARDS was defined 
as: the acute onset of respiratory failure, bilateral infiltrates 
on chest radiograph, hypoxemia as defined by a PaO2/FiO2 
ratio ≤200 mmHg, and no evidence of left atrial hypertension or 
a pulmonary capillary pressure <18 mmHg (if measured) to rule 
out cardiogenic edema. In addition, Acute Lung Injury (ALI), 
the less severe form of acute respiratory failure, was different 
from ARDS only for the degree of hypoxemia, in fact it was 
defined by a 200 < PaO2/FiO2 ≤300 mmHg. 
Over the past 18 years of practice, the diagnostic accuracy 
of the ARDS definition by AECC has been questioned. In 
a series of 138 ARDS patients, the definition had relatively 
low specificity (51%) when compared with autopsy findings 
demonstrating diffuse alveolar damage as assessed by two 
independent pathologists (10). The reliability of the chest 
radiographic criteria of ARDS has been demonstrated to be 
moderate, with substantial interobserver variability (11,12). In 
addition, the hypoxemia criterion (i.e. PaO2/FiO2 <200 mmHg) 
can be markedly affected by the patient’s ventilator settings, 
especially the PEEP level used (13). Finally, the wedge pressure 
can be difficult to interpret and if a patient with ARDS develops 
a high wedge pressure that should not preclude diagnosing that 
patient as having ARDS. Based on these concerns, the European 
Society of Intensive Care Medicine with endorsement from 
the American Thoracic Society and the Society of Critical Care 
Medicine convened an international expert panel to revise the 
ARDS definition (14); the panel met in 2011 in Berlin, and 
hence the new definition was coined the Berlin definition. The 
goal of developing the Berlin definition was to try and improve 
feasibility, reliability, face and predictive validity (14). Of 
interest, this definition was empirically evaluated for predictive 
validity for mortality compared with the AECC definition, using 
data derived from multi and single center clinical trials (14). 
There are a few key modifications (oxygenation, timing of acute 
onset, Chest X-ray, and wedge pressure criterion) in the Berlin 
definition as compared with the AECC definition.
Oxygenation
In the Berlin definition, there is no use of the term Acute 
Lung Injury (ALI). The committee felt that this term was used 
inappropriately in many contexts and hence was not helpful. 
In the Berlin definition, ARDS was classified as mild, moderate 
and severe according to the value of PaO2/FiO2 ratio (Table 1). 
Importantly, the PaO2/FiO2 ratio value is considered only with a 
CPAP or PEEP value of at least 5 cmH2O. 
Timing of acute onset
The timing of acute onset of respiratory failure to make diagnosis 
of ARDS is clearly defined in Berlin definition. It defines the 
exposure to a known risk factor or worsening of the respiratory 
symptoms within one week. It is important to identify risk 
factors that explain the context of acute respiratory failure arised 
from (Table 2).
Chest X-ray 
The chest radiograph is characterized by bilateral opacities 
involving at least 3 quadrants that are not fully explained by 
pleural effusions, atelectasis and nodules. In the absence of known 
risk factors, a cardiogenic origin of edema is to be excluded by 
objective evaluation of cardiac function with echocardiography. 
Consequently, the wedge pressure measurement was abandoned 
because ARDS may coexist with hydrostatic edema caused by 
fluid overload or cardiac failure (8).
The ARDS Berlin definition was empirically evaluated to test 
predictive validity for mortality (14) by using a large clinical 
database from multicenter and single center clinical trials that 
included 3,670 patients. The mortality rate was 27% for mild, 
32% for moderate and 45% for severe ARDS. Moreover, the 
number of ventilator free days declined from mild to severe 
ARDS, and the more severe stages of ARDS were associated with 
a progressive increase in lung weight as evaluated by CT scan 
and shunt fraction.
 .Current therapies
Numerous clinical studies have been conducted in patients with 
ARDS, but great advances in the care of the patients are still 
lacking and supportive therapies remain the mainstay in the 
ARDS management.
Protective mechanical ventilation
There is a large body of evidence from experimental and clinical 
studies demonstrating that mechanical ventilation, particularly 
in the setting of lung injury, can exacerbate functional and 
structural alterations in the lung (15). It is noteworthy that 
mechanical ventilation not only perpetuates lung injury, 
but also contributes to both the morbidity and mortality of 
ARDS (2,16,17). The concept that the limitation of end 
inspiratory lung stretch may reduce mortality in ARDS patients, 
culminated in the NIH-sponsored multicenter study of patients 
with ARDS (1,18). In this trial, patients randomized to receive 
a lower tidal volume (Vt) [4-6 mL/kg predict body weight 
(PBW), and maintenance of plateau pressure between 25 and 30 
cmH2O] had a survival benefit. Mortality was reduced from 40% 
in the conventional arm to 31% in the low Vt arm (CI, 2.4-15.3% 
difference between groups) (1). The benefit in terms of mortality 
and ventilation free days did not appear to be related to the value 
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of the lung compliance at baseline or to the underlying risk factor 
for ARDS (19). Of note, the survival benefit was associated 
with a reduction of plasma IL-6 concentration, supporting the 
hypothesis that a lung protective strategy limits the spill over 
into the systemic circulation of inflammatory mediators, which 
in turn may induce multiple system organ failure (17). 
In addition to lung over-distention, cyclic opening and closing 
of small airways and alveolar units (so called atelectrauma) 
can also lead to lung injury (20,21). Several clinical trials have 
been conducted in ARDS patients to examine the effects of an 
“open lung” approach in which the application of recruitment 
maneuvers and higher levels of PEEP may limit atelectrauma. 
In two randomized studies, Amato and colleagues, and Villar 
and colleagues examined the effect of a composite strategy that 
minimized tidal volume, adopted lung recruitment maneuvers, 
and applied a level of PEEP above the closing pressure of the 
lung (22,23). Although the intervention arms decreased 
mortality, the studies were criticized due to relatively small 
sample sizes and relatively high mortality in the control arms. The 
ARDS Network performed a second large clinical trial comparing 
lower vs. higher levels of PEEP (the ALVEOLI study) (24). 
The trial was stopped early for futility, showing a trend to 
worse outcome in the higher PEEP arm, although there was 
an imbalance in patient characteristics at baseline favoring the 
control arm; the mean age of the higher PEEP arm was higher 
(54±17 vs. 49±17, P<0.05), the mean PaO2/FiO2 was lower 
(151±67 vs. 165±77, P<0.05), and there was a trend to higher 
APACHE III scores, at baseline. 
Similar results were obtained in the Canadian Lung Open 
Ventilation (LOV) (25) clinical trial. The PEEP values were 
slightly higher compared to those of the previous ALVEOLI 
study. The conventional arm received levels of PEEP similar to 
the ARMA study. The study enrolled 985 patients and it failed to 
demonstrate any difference in mortality in the two groups (36.4% 
and 40.4% in the treatment and control groups respectively). 
The use of rescue therapies and death from refractory hypoxemia 
were less in the LOV - higher PEEP group. A French multi-centre 
randomized control trial (EXPRESS study) (26) addressed the 
superiority of an open lung approach in which PEEP was titrated 
to the highest value possible keeping Pplat <28-30 cmH2O. 
In the control arm, PEEP was set between 5 and 9 cmH2O. In 
both groups Vt was <6 mL/kg PBW. Patient treated according 
Table 1. ARDS Berlin definition.
The Berlin definition of acute respiratory distress syndrome
Timing Within 1 week of a known clinical insult or new or worsening respiratory symptoms
Chest imaginga Bilateral opacities — not fully explained by effusions, lobar/lung collapse, or nodules
Origin of edema
Respiratory failure not fully explained by cardiac failure or fluid overload.
Need objective assessment (e.g., echocardiography) to exclude hydrostatic edema if no risk factor present
Oxygenationb
Mild 200 mmHg < PaO2/FIO2 ≤300 mmHg with PEEP or CPAP ≥5 cmH2O
c
Moderate 100 mmHg < PaO2/FIO2 ≤200 mmHg with PEEP ≥5 cmH2O
Severe PaO2/FIO2 ≤100 mmHg with PEEP ≥5 cmH2O
Abbreviations: CPAP, continuous positive airway pressure; FIO2, fraction of inspired oxygen; PaO2, partial pressure of arterial oxygen; PEEP, 
positive end-expiratory pressure; aChest radiograph or computed tomography scan; bIf altitude is higher than 1,000 m, the correction factor 
should be calculated as follows: [PaO2/FIO2_(barometric pressure/760)]; 
cThis may be delivered noninvasively in the mild acute respiratory 
distress syndrome group.
Table 2. Common risk factors for ARDS
Direct Indirect
Pneumonia Non-pulmonary sepsis
Aspiration of gastric contents Major trauma
Inhalational injury Pancreatitis
Pulmonary contusion Severe burns
Pulmonary vasculitis Non-cardiogenic shock
Drowning Drug overdose
Multiple transfusions or transfusion associated acute lung injury (TRALI)
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to the open lung approach had significantly more ventilator free 
days and organ failure free days; however, hospital, 28-day and 
60-day mortality were not different between the study groups, 
patients. Of note, patients who now would be considered to have 
moderate to severe lung injury (P/F <200) tended to have lower 
28-day mortality in the higher PEEP group compared to patients 
treated with lower PEEP. 
A recent meta-analysis that incorporated trials (from 1996 
to January 2010) comparing higher vs. lower levels of PEEP 
concluded that there is no difference in mortality applying lower 
vs. higher levels of PEEP in patients with mild ARDS. However, in 
the subgroup of patients with severe ARDS, as defined by a PaO2/
FiO2 <200, there was be a benefit from higher levels of PEEP (27).
Non conventional therapies in severe ARDS
Historically prone positioning, high frequency oscillatory 
ventilation and extracorporeal membrane oxygenation have 
been proposed as non-conventional therapies for life-threatening 
refractory hypoxemia in severe ARDS patients (28). Although 
all these strategies have demonstrated to improve oxygenation, 
their impact on mortality is controversial. In fact, two recent 
RCT have questioned the safety of HFOV (29,30), where 
promising results come from a French study in which mortality 
was significantly lower in patients treated with extended period 
of prone position (28). 
The prone positioning exploits gravity and re-positioning 
of the heart in the thorax to recruit the lung and to improve 
ventilation perfusion matching. Despite improving arterial 
oxygenation (31,32), prone position failed to show a significant 
improvement in mortality (32). In a subsequent study, prone 
ventilation was associated with a decrease in (37.8% vs. 46.1%) 
28-day mortality in the subgroup of patients with severe 
hypoxemia, but given the small numbers, definitive conclusions 
cannot be drawn regarding the effect on mortality in this 
subgroup (32). However, pending results from a recent French 
study seem to clearly demonstrate a lower mortality in patients 
with severe ARDS who were treated with longer period of prone 
position.
In theory, high frequency oscillatory ventilation (HFOV) 
encapsulates the main principles of lung protection: it delivers 
extremely small tidal volumes around a relatively high mean 
airway pressure, at high respiratory frequencies (3-15 Hz), 
with the goal of avoiding tidal overstretch and recruitment/
derecruitment (33,34). Despite the strong physiological 
rationale and preliminary human studies (35,36) showing 
improvement in oxygenation two recent large clinical trials 
(29,30) of HFOV in patients with moderate/severe ARDS failed 
to show any improvement in survival and have questioned safety 
of HFOV. Both trials compared HFOV to a lung protective 
strategy that employed low tidal volume and higher PEEP levels 
to fully recruit the lung. In the OSCAR study 398 patients were 
randomized to HFO and 397 patients to a conventional lung 
protective strategy. There was no difference in mortality between 
the two groups (HFOV 42% vs. conventional ventilation 41%). 
In the OSCILLATE study, an excess mortality was reported in 
the HFOV arm and the trial was stopped early after enrolling 
548 patients instead of planned 1,200 patients. In-hospital 
mortality was 47% in the HFO group compared to 35% in 
the control group (relative risk of death with HFO, 1.33; 95% 
confidence interval, 1.09 to 1.64; P=0.005). In addition, 11% 
of patients in the conventional arm crossed over to HFOV arm 
for refractory hypoxemia and despite this the death rates due 
to refractory hypoxemia were not different between groups. 
Possible factors that might explain this excess mortality in the 
HFOV arm are a greater use of sedation, neuromuscular blocker 
use, and longer and higher rates of vasoactive drugs. In light of 
these considerations, the results of these two studies preclude 
the routine use of this strategy in patients with ARDS (37).
In patients with severe hypoxemic and/or hypercapnic 
respiratory failure, extracorporeal lung support (ECLS) 
techniques, including extracorporeal membrane oxygenation 
(ECMO), have been considered to be possible rescue therapies. 
The aim of this strategy is to overcome severe hypoxemia 
and respiratory acidosis while keeping the lung completely at 
rest. Despite earlier negative trials (38,39), the CESAR study 
suggested the benefit of ECLS in patients with severe ARDS. In 
this RCT, 180 patients were randomized to receive veno-venous 
ECMO (after transfer to a specialized center) or conventional 
mechanical ventilation (in regional centres). The former group 
had a better 6 months survival than the latter one, but critics 
argue that the ECMO patients received a best practice treatment 
in specialized centers, while the control group treatment was 
left to the discretion of physicians in multiple non-specialized 
hospitals (40). Currently there is a French-led international 
multicenter randomized trial evaluating the impact of early 
veno-venous ECMO treatment in patients with ARDS, in terms 
of morbidity and mortality in the first 30, 60 and 90 days. The 
results are expected around January 2014.
ARDS therapies other than mechanical ventilation
Over the last decade, several non-ventilatory treatments have 
been investigated to further improve the outcome of ARDS 
patients. In particular, we will focus on the role of conservative 
fluid strategy and the putative role of neuromuscular blocking 
agents (8,41).
In ARDS patients, alveolar edema formation caused by 
increased vascular permeability may be worsened by higher 
hydrostatic pressure as a consequence of fluid overload. Of 
note, positive fluid balance, higher values of central venous 
and capillary wedge pressures are independent risk factors for 
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mortality in critical ill patients. To examine whether a more 
fluid-conservative strategy would impact outcomes, ARDSnet 
sponsored a RCT to evaluate the effects of fluid therapy strategy 
aimed to limit the net fluid balance in ARDS patients without 
shock and renal failure requiring replacement therapy (8). 
Mortality at 60 days was not different between the two study 
groups. However, patients randomized to fluid restriction 
had more mechanical ventilation free days and a lower ICU 
length of stay compared to those patients randomized to liberal 
fluid intake. The two study groups were different in terms of 
cumulative fluid balance; in particular the liberal fluid group had 
positive fluid balance of 7 liters in one week with 1 L of net fluid 
gain each day (8).
In patients with severe ARDS as defined by PaO2/FiO2 <150, 
48 hrs administration of non depolarizing neuromuscular 
blocking agent (NMBA) cisatracurium has been shown to 
improve oxygenation, and adjusted 90-day survival, as well as 
decreasing duration of mechanical ventilation and barotrauma, 
without increasing muscle weakness (41). Moreover, NMBAs 
have been shown to reduce levels of both pulmonary and 
systemic pro-inflammatory mediators (42). However, given the 
potential side effects of these medications in terms of critical 
illness neuromyophathy (CINM), its use should be limited to 
severe hypoxemic patients for a brief period.
Inhaled nitric oxide for its pulmonary vasodilator effects 
has been proposed to treat refractory hypoxemia reestablishing 
an adequate ventilation perfusion matching. Both recent 
randomized clinical trials (43,44) and robust meta-analyses 
(45,46) indicate that inhaled nitric oxide improves oxygenation 
over a 24 hour period of treatment. However, no benefit has been 
demonstrated on mortality. In addition, detrimental effects on 
kidney function have been documented thus limiting its cautious 
use to patients with severe ARDS and pulmonary hypertension.
 .Future non-ventilatory therapeutic options
In the last decade many molecular mechanisms have been 
discovered which greatly increase our understanding of ARDS 
pathogenesis. However, none of these new advances have been 
translated into effective therapies to improve outcome of ARDS 
patients. New therapeutic opportunities may come from gene 
and mesenchymal stem cells therapies. In the next sections 
of this review we will summarize the new findings of gene 
and mesenchymal stem cell therapies in animal models; these 
approaches hold promise in the treatment of ARDS.
Gene therapy for ALI/ARDS
Epithelial damage after lung injury is characterized by apoptosis 
and necrosis of type I and II alveolar cells. Epithelial damage 
dramatically contributes to alveolar edema formation, which is 
associated with increased permeability; airspace infiltration by 
neutrophils amplifies and sustains the lung injury. After the acute 
exudative phase, alveolar edema clearance and proliferation and 
differentiation of type I into type II alveolar epithelial cells lead 
to resolution of lung injury. Abnormal tissue repair, depending 
on the severity of tissue damage, leads to extracellular matrix 
deposition and fibrosis. 
In the acute exudative phase alveolar flooding associated with 
an impaired alveolar fluid clearance is the main determinant 
of ventilation perfusion mismatch and subsequent hypoxia in 
ARDS patients. This has led to extensive research to reestablish 
alveolar fluid clearance and keep the lung dry. The driving force 
for fluid reabsorption is based on the active transport of Na+ 
from the alveolar space into the interstitial space. The Na+, K+ 
transporting adenosine - 5'- triphosphate (Na+/K+-ATPase) 
together with others ion transporters such as epithelial Na+ 
channel (ENaC), the cystic fibrosis transmembrane conductance 
regulator (CFTR) create an osmotic gradient which reabsorbs 
fluid from the alveolar spaces.
Based on these physiological mechanisms, recent clinical 
trials have tested beta agonist administration as pharmacological 
intervention in patients with ARDS. In fact, several in vitro 
and animal studies have previously shown that beta agonist 
as salbutamol activate β-2 receptors on alveolar type-1 and 
type-2 cells, which increase intracellular cyclic adenosine 
monophosphate (cAMP), leading mainly to increased AFC. In 
2011 the ARDS-net sponsored the ALTA study in which 282 
patients with acute lung injury, as defined by PaO2 and FiO2 ratio 
of 300 or less, were randomized to receive aerosolized salbutamol 
(at dose of 5 mg) or placebo every 4 hours for up to 10 days (47). 
Unfortunately, the trial was stopped earlier because the primary 
end point, ventilator free days (VFDs), had crossed predefined 
futility boundaries. More recently, a large multicenter RCT, 
performed across 46 ICUs in the United Kingdom, showed that 
intravenous salbutamol is even hazardous for patients with early 
and severe ARDS (48). In fact, patients treated with salbutamol 
at dose of 15 μg/kg ideal bodyweight/h had higher mortality 
at 28 days and lower ventilator and organ failure free days. The 
reason of these unfavorable outcomes seems to be related to 
higher rates of side effects as tachycardia, arrhythmias, and lactic 
acidosis in the interventional arm.
Based on the negative results of these large RCTs, gene 
therapy approaches to restore and potentiate the Na+ movement 
across the alveolar epithelial barrier could be promising 
strategies to overcome the problem of systemic side effects of 
beta 2 receptors agonists. Transfer of α2 subunit or β1 subunit 
of Na+/K+ ATPase has been demonstrated to increase the 
expression of Na+/K+ ATPase on alveolar epithelial cells and 
to improve alveolar fluid clearance (49,50). In a mouse model 
of LPS induced lung injury, plasmid transfer of genes encoding 
the α1 and β1 subunits of the Na+/K+-ATPase were delivered to 
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the lungs of mice using transthoracic electroporation. Delivery 
of plasmids expressing Na+, K+-ATPase subunits protected the 
lung from subsequent injury and partially reversed existing 
lung injury as demonstrated by a reduction of wet-to-dry ratios, 
bronco-alveolar lavage protein levels and an improvement 
of alveolar fluid clearance, and respiratory mechanics (51). 
Moreover, Adir and colleagues showed that overexpression 
of α2 or β1 subunit of Na+/K+ ATPase significantly improved 
alveolar fluid clearance (AFC) not only in normal lungs but 
also in those exposed to ventilator induced lung injury (50,52). 
Seven days before the beginning of mechanical ventilation, rats 
were treated with adenovirus that expressed α2 or β1 subunit 
of Na-K-ATPase. This gene therapy approach prevented the 
50% reduction of AFC caused by VILI (50). Beta-adrenergic 
agonists improve Na+ transport mediated by Na+/K+ ATPase 
increasing the intracellular levels of cAMP. The adenovirus-
induced overexpression of beta 2 adrenergic receptor gene 
greatly improved AFC increasing the expression of both ENaC 
and Na+/K+ ATPase (53).
A number of studies have demonstrated the role of growth 
factors in increasing AFC. In a mouse model of hyperoxia and 
oleic acid induced acute lung injury, liposome transfer of gene 
encoding keratinocyte growth factor attenuated lung injury likely 
increasing the proliferation of alveolar epithelial cells (54,55).
Lung injury in ARDS is characterized by a pro-inflammatory 
increase in vascular permeability and neutrophil infiltration, 
which sustain alveolar edema and damage to alveolar barrier. 
Several studies have focused on the role of gene therapy in 
modulating the pro-inflammatory response in the lung. Lung 
gene transfer encoding for IL10 has been shown to reduce the 
release of inflammatory cytokines in an ex vivo model of donor 
lungs before transplantation. Ten lungs of brain death patients, 
who did not match the criteria for transplantation, received 
12 hour of normothermic ex vivo lung perfusion with or without 
the intra-tracheal delivery of adenoviral vector encoding human 
interleukin-10 (AdhIL-10). The lungs treated with this gene 
therapy approach demonstrated better graft function with 
improvement in oxygenation, pulmonary vascular resistance, 
and an increase in anti-inflammatory cytokines release (56). 
Moreover, in IL-10 knock out mice, chronically infected with 
Pseudomonas Aeruginosa, the adeno virus transfer of gene 
encoding for IL-10 produced a significant anti-inflammatory 
effect. Treated animals showed a reduction of IL-1β, TNFα and 
macrophage inhibitory protein (MIP)-1α release into the airway 
spaces. Moreover, this gene transfer mitigated neutrophil lung 
infiltration (57). Similar anti-inflammatory effects have been 
found with the delivery of genes encoding anti-inflammatory 
cytokines such as interferon protein 10 (IP-10) (58), IL 12 (59) 
and transforming growth factor beta-1 (TGF-β1) (60). 
Heme oxygenases (HO) are essential enzymes, which degrade 
heme into carbon monoxide (CO), biliverdin and free iron. 
Due to its anti-inflammatory, anti-apoptotic and, as recently 
described, anti-viral properties the inducible HO isoform HO-1 
is an important molecule which has been used in different genetic 
approaches to mitigate acute lung injury (61-63). Gene transfer of 
HO-1 provided lung protection against hyperoxia, influenza virus 
pneumonia and endotoxin mediated lung injury (61-63). 
Mesenchymal stem cells
Mesenchymal stem cells (MSC) are multipotent stromal cells 
that can differentiate into a variety of cells types including 
osteoblasts, chondrocytes, adipocytes, etc. These cells can be 
isolated not only from bone marrow but also from fat, umbilical 
cord blood, placental tissue, skeletal muscle, and tendons. 
The International Society of Cellular Therapy published the 
criteria to identify MSCs: (I) adherence to plastic surfaces; (II) 
expression of CD105, CD73, CD90, without expressing CD45, 
CD34, CD14, CD11b, CD79α, CD19 and human leukocyte 
antigen (HLA) II; and (III) the ability to differentiate into 
osteoblast, adipocytes, and chondroblasts in vitro.
MSCs have several properties that make them promising as a 
therapeutic approach in ARDS. MSCs differentiating into several 
cell types have regenerative properties and may repair damaged 
tissues. In addition, they can release many molecules, which 
contribute to immunomodulatory and anti-inflammatory effect. 
Moreover, MSCs lacking the HLA II molecules may escape the 
immune response after allogenic or xenogenic transplantation 
and may be used as carriers for gene therapy.
Recent findings describe a therapeutic role of MSCs in 
animal models of ARDS and sepsis. MSCs may attenuate the 
local and systemic inflammatory response in different mouse 
models of sepsis, predominantly through their paracrine 
immune-modulatory effect, despite their limited engraftment 
and differentiation in alveolar epithelial cells (64). Mei and 
colleagues demonstrated the immune modulatory effect of 
MSCs in a mouse model of LPS associated acute lung injury. The 
systemic administration of MSCs 30 minutes after LPS injection 
was associated with reduction in total cell and neutrophil 
counts in bronco-alveolar lavage (BAL) fluid as well as in pro-
inflammatory cytokines in both BAL fluid and lung parenchyma 
homogenate. Of interest, the authors showed the role of MSC 
as carriers for the vasculo-protective gene angiopoietin 1 
(ANGPT1). Mice treated with MSCs transfected with ANGPT1 
had complete restoration of lung vascular permeability (65). 
Moreover, these results were expanded in a mouse model 
of sepsis in which the MSC therapy not only attenuated the 
systemic inflammatory response and organ dysfunction, but 
also improved bacterial clearance and survival trough the 
enhancement of phagocytic activity (66). Thus, MSCs seem to 
be potent immunomodulators; they may interact with circulating 
and tissue monocytes and macrophages and reprogram them to 
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enhance an anti-inflammatory response. 
Nemeth and colleagues demonstrated that monocytes 
and macrophages treated with MSCs produced large amount 
of the anti-inflammatory cytokine IL 10; in contrast, plasma 
concentrations of TNFα and IL 6 were reduced. The temporal 
reprogramming of monocytes induced by MSCs seems to be 
in part related to the production of prostaglandin E2 (PGE2) by 
MSCs. PGE2 acting on the EP2 and EP4 macrophage receptors 
stimulate the production of IL 10 (67).
 .Conclusions
ARDS still represents a deadly form of respiratory failure with 
long term consequences in patient survivors and indeed, their 
families (68,69). Supportive therapies represent the mainstay 
of treatment of ARDS, whereas the limitation of end end-
inspiratory lung stretch has been clearly demonstrated to reduce 
the ARDS associated mortality. Adoption of the new definition 
may be useful to better classify patients according to severity and 
prognosis. Lacking of effective therapies relies on the complex 
pathogenesis of the syndrome characterized by different 
overlapping signaling pathways Gene therapy and mesenchymal 
stem cells may be promising novel therapeutic strategies aimed 
at modulate key pathophysiologic mechanisms of ARDS.
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